- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03439046
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)
A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib Plus Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main purpose of this local, multicenter study is to investigate genetic and gene expression alterations in tumor prior to and following progression on ribociclib, during core phase and then prior to and following progression on alpelisib and thus identify patterns of mutations, how they evolve, and their association with CDK4/6 inhibition and outcomes such as sustained response or early progression. The study also aims to evaluate pharmacogenomics and its association with adverse events (frequency and severity), drug-drug interactions and clinical outcomes.
Finally, the study will also generate additional long-term safety and efficacy data in this specific Italian population.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Napoli, Italy, 80131
- Novartis Investigative Site
-
Napoli, Italy, 80138
- Novartis Investigative Site
-
-
AL
-
Casale Monferrato, AL, Italy, 15033
- Novartis Investigative Site
-
-
BA
-
Bari, BA, Italy, 70124
- Novartis Investigative Site
-
-
BG
-
Bergamo, BG, Italy, 24127
- Novartis Investigative Site
-
-
BN
-
Benevento, BN, Italy, 82100
- Novartis Investigative Site
-
-
BO
-
Bologna, BO, Italy, 40138
- Novartis Investigative Site
-
-
BR
-
Brindisi, BR, Italy, 72100
- Novartis Investigative Site
-
-
BS
-
Brescia, BS, Italy, 25123
- Novartis Investigative Site
-
-
CR
-
Cremona, CR, Italy, 26100
- Novartis Investigative Site
-
-
CT
-
Catania, CT, Italy, 95124
- Novartis Investigative Site
-
Catania, CT, Italy, 95123
- Novartis Investigative Site
-
-
FE
-
Cona, FE, Italy, 44100
- Novartis Investigative Site
-
-
FG
-
San Giovanni Rotondo, FG, Italy, 71013
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italy, 16132
- Novartis Investigative Site
-
-
LI
-
Livorno, LI, Italy, 57124
- Novartis Investigative Site
-
-
MB
-
Monza, MB, Italy, 20900
- Novartis Investigative Site
-
-
MC
-
Macerata, MC, Italy, 62100
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Italy, 98158
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20133
- Novartis Investigative Site
-
Milano, MI, Italy, 20132
- Novartis Investigative Site
-
Milano, MI, Italy, 20141
- Novartis Investigative Site
-
Rozzano, MI, Italy, 20089
- Novartis Investigative Site
-
-
NU
-
Nuoro, NU, Italy, 08100
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Italy, 90127
- Novartis Investigative Site
-
Palermo, PA, Italy, 90146
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italy, 35100
- Novartis Investigative Site
-
-
PG
-
Perugia, PG, Italy, 06129
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italy, 56126
- Novartis Investigative Site
-
-
PN
-
Aviano, PN, Italy, 33081
- Novartis Investigative Site
-
-
PO
-
Prato, PO, Italy, 59100
- Novartis Investigative Site
-
-
PU
-
Fano, PU, Italy, 61032
- Novartis Investigative Site
-
-
RA
-
Faenza, RA, Italy, 48018
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00168
- Novartis Investigative Site
-
Roma, RM, Italy, 00128
- Novartis Investigative Site
-
Roma, RM, Italy, 00189
- Novartis Investigative Site
-
-
SA
-
Salerno, SA, Italy, 84131
- Novartis Investigative Site
-
-
TO
-
Candiolo, TO, Italy, 10060
- Novartis Investigative Site
-
Torino, TO, Italy, 10128
- Novartis Investigative Site
-
-
UD
-
Udine, UD, Italy, 33100
- Novartis Investigative Site
-
-
VR
-
Negrar, VR, Italy, 37024
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
CORE PHASE Inclusion Criteria:
- Patient has an advanced (locoregionally recurrent or metastatic) breast cancer in first line treatment (treatment naïve for the advanced setting).
- Patient is in post-menopause, defined by one of the following:
- Prior bilateral oophorectomy
- Age ≥60
- Age <60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifen, or ovarian suppression) and FSH and estradiol in the postmenopausal range per local normal range
- Patient has a histologically and/or cytologically confirmed diagnosis of estrogenreceptor positive and/or progesterone receptor positive breast cancer by local laboratory.
- Patient has an HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.
- Patient is willing to undergo blood and tumor sample collection for the biological assessments/objectives as scheduled in the protocol.
CORE PHASE Exclusion Criteria:
- Patient who received prior treatment with any CDK4/6 inhibitor.
- Patient who received any prior systemic hormonal therapy or chemotherapy for advanced breast cancer.
Note:
Patients who received neo/adjuvant therapy for breast cancer are eligible. If the prior neo/adjuvant therapy included letrozole or anastrozole, the disease-free interval must be greater than 12 months from the completion of treatment until study entry.
• Patients who received ≤ 28 days of letrozole or anastrozole for advanced disease prior to inclusion in this trial are eligible.
- Patient is currently using other anti-cancer therapy. Other protocol-defined inclusion/exclusion criteria may apply.
EXTENSION PHASE Inclusion criteria:
- Patient has been discontinued (any reason allowed) from treatment with ribociclib + letrozole in the core phase and is deemed suitable for treatment with alpelisib + fulvestrant in second line. Ribociclib + letrozole must be the last treatment regimen before alpelisib + fulvestrant.
- Patient has PIK3CA mutation as determined in tumor tissue and/or plasma by a Novartis designated laboratory. Results of tissue samples obtained during the core phase (screening or EOT) are acceptable
EXTENSION PHASE Exclusion criteria:
- Patient has received prior treatment with any PI3K inhibitors.
- Patient is concurrently using other anti-cancer therapy. Ribociclib and letrozole used in the core phase must be discontinued at least 7 days prior to day one of the extension study treatment.
All drugs with overlapping toxicities must be discontinued within 7 days and AE resolved to NCI CTCAE v4.03 Grade ≤1 prior to study treatment. Exception to this criterion: patients with any grade of alopecia are allowed to enter the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ribociclib+letrozole
Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
|
Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
Other Names:
Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
|
Experimental: alpelisib+fulvestrant
Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
|
Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
Other Names:
Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline ctDNA alterations to progression disease during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of patients with ctDNA alterations (i.e.
such as but not limited to Rb, ESR1, cyclin D1, CDKN2A, PIK3CA, p53 and PTEN) will be provided over time to characterize the biological evolution of the disease in each patient.
The association of these alterations with clinical outcomes will also be provided.
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline serum TK1 concentrations to progression disease during core phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase
|
Descriptive statistics of serum TK1 concentrations will be provided over time.
The association/correlation of serum TK1 concentrations with clinical outcomes will also be provided.
|
Up to approximately 36 months starting from Baseline of the core phase
|
The percentage of patients with ctDNA alterations will be provided over time in the subsets during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of patients with ctDNA alterations will be provided over time in the subsets of long responder patients and those with early progression
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Change from baseline tumor mutational burden (TMB) to progression disease during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Descriptive statistics of tumor mutational burden (TMB), defined as a quantitative measure of the total number of ctDNA mutations per coding area of tumor genome, will be provided over time, according to the scheduled sample collections.
The association of TMB values with clinical outcomes will also be provided.
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of patients with mutations as assessed at baseline of the Core and Extension phase across different patient profiles
Time Frame: Screening Core Phase and Screening Extension Phase
|
The percentage of patients with mutations as assessed at baseline by means of ctDNA sample, and tissue biopsy will be compared between the following patient profiles defined according to disease history (i.e.
newly diagnosed vs. recurrent disease).
|
Screening Core Phase and Screening Extension Phase
|
The percentage of patients with alterations detected through liquid biopsy vs. tissue biopsy during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of patients with alterations detected at baseline and at disease progression will be compared between the two different procedures of detection (i.e.
detection through liquid biopsy vs. tissue biopsy).
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Change from baseline tumor microenvironment parameters to progression disease during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Descriptive statistics of tumor microenvironment parameters on tumor biopsy will be provided at baseline and upon disease progression.
The association of these tumor micro-environment parameters with clinical outcomes will also be provided.
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Time-to-Progression (TTP) during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Time to progression (TTP) is defined as time from date of start of treatment to the date of event defined as the first documented progression or death due to underlying cancer.
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The number of patients with adverse events as a measure of safety and tolerability during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Fequency and severity of AEs and SAEs
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of patients with best overall response rate CR or PR during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Overall response rate (ORR) is defined as the percentage of patients, with measurable disease, that showed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of patients with clinical benefit during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Clinical benefit rate (CBR) is defined as the percentage of patients with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks.
CR, PR and SD are defined according to RECIST 1.1.
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
The percentage of participants with adverse events as a measure of safety and tolerability during Core and Extension Phase
Time Frame: Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Frequency and severity of AEs and SAEs
|
Up to approximately 36 months starting from Baseline of the core phase and Up to approximately 9 months starting from Baseline of the extension phase
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Letrozole
- Fulvestrant
Other Study ID Numbers
- CLEE011AIT01
- 2017-004176-62 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
Clinical Trials on Ribociclib
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Fox Chase Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Nader SanaiNovartis; Barrow Neurological Institute; Ivy Brain Tumor CenterActive, not recruitingGlioblastoma Multiforme | MeningiomaUnited States
-
Assaf-Harofeh Medical CenterUnknownSoft-Tissue Sarcoma | Liposarcomas, Dedifferentiated | Liposarcoma - Well Differentiated | Liposarcoma; Mixed TypeIsrael
-
Children's Hospital Medical Center, CincinnatiNovartisTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Bithalamic High Grade GliomaUnited States
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Hadassah Medical OrganizationUnknownSoft Tissue Sarcoma | LiposarcomaIsrael